nodes	percent_of_prediction	percent_of_DWPC	metapath
Deferoxamine—XDH—Doxorubicin—sarcoma	0.642	1	CbGbCtD
Deferoxamine—XDH—Effects of Nitric Oxide—MB—sarcoma	0.0604	0.7	CbGpPWpGaD
Deferoxamine—XDH—Effects of Nitric Oxide—HBA1—sarcoma	0.0218	0.252	CbGpPWpGaD
Deferoxamine—XDH—Selenium Micronutrient Network—HBA1—sarcoma	0.0032	0.0371	CbGpPWpGaD
Deferoxamine—Urethral disorder—Vincristine—sarcoma	0.00103	0.00377	CcSEcCtD
Deferoxamine—Erythema—Dactinomycin—sarcoma	0.00102	0.00375	CcSEcCtD
Deferoxamine—Bone pain—Epirubicin—sarcoma	0.000988	0.00363	CcSEcCtD
Deferoxamine—Bone disorder—Doxorubicin—sarcoma	0.000969	0.00356	CcSEcCtD
Deferoxamine—Vision blurred—Thiotepa—sarcoma	0.000968	0.00356	CcSEcCtD
Deferoxamine—Angiopathy—Vincristine—sarcoma	0.000949	0.00349	CcSEcCtD
Deferoxamine—Infestation NOS—Etoposide—sarcoma	0.000944	0.00347	CcSEcCtD
Deferoxamine—Infestation—Etoposide—sarcoma	0.000944	0.00347	CcSEcCtD
Deferoxamine—Mediastinal disorder—Vincristine—sarcoma	0.000943	0.00347	CcSEcCtD
Deferoxamine—Injection site reaction—Epirubicin—sarcoma	0.000941	0.00346	CcSEcCtD
Deferoxamine—Renal failure—Etoposide—sarcoma	0.000928	0.00341	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Etoposide—sarcoma	0.000926	0.0034	CcSEcCtD
Deferoxamine—Leukopenia—Thiotepa—sarcoma	0.000919	0.00338	CcSEcCtD
Deferoxamine—Bone pain—Doxorubicin—sarcoma	0.000914	0.00336	CcSEcCtD
Deferoxamine—Leukopenia—Dactinomycin—sarcoma	0.000913	0.00335	CcSEcCtD
Deferoxamine—Arrhythmia—Mitoxantrone—sarcoma	0.00091	0.00335	CcSEcCtD
Deferoxamine—Convulsion—Thiotepa—sarcoma	0.00089	0.00327	CcSEcCtD
Deferoxamine—Neuropathy—Epirubicin—sarcoma	0.000888	0.00326	CcSEcCtD
Deferoxamine—Erythema—Mitoxantrone—sarcoma	0.000887	0.00326	CcSEcCtD
Deferoxamine—Arthralgia—Thiotepa—sarcoma	0.000875	0.00321	CcSEcCtD
Deferoxamine—Myalgia—Thiotepa—sarcoma	0.000875	0.00321	CcSEcCtD
Deferoxamine—Injection site reaction—Doxorubicin—sarcoma	0.00087	0.0032	CcSEcCtD
Deferoxamine—Cramps of lower extremities—Epirubicin—sarcoma	0.000869	0.00319	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—sarcoma	0.000868	0.00319	CcSEcCtD
Deferoxamine—Myalgia—Dactinomycin—sarcoma	0.000868	0.00319	CcSEcCtD
Deferoxamine—Urinary tract disorder—Etoposide—sarcoma	0.000837	0.00308	CcSEcCtD
Deferoxamine—Vision blurred—Mitoxantrone—sarcoma	0.000836	0.00307	CcSEcCtD
Deferoxamine—Infection—Thiotepa—sarcoma	0.000833	0.00306	CcSEcCtD
Deferoxamine—Oedema—Dactinomycin—sarcoma	0.000832	0.00306	CcSEcCtD
Deferoxamine—Urethral disorder—Etoposide—sarcoma	0.000831	0.00305	CcSEcCtD
Deferoxamine—Infection—Dactinomycin—sarcoma	0.000827	0.00304	CcSEcCtD
Deferoxamine—Nervous system disorder—Thiotepa—sarcoma	0.000822	0.00302	CcSEcCtD
Deferoxamine—Neuropathy—Doxorubicin—sarcoma	0.000822	0.00302	CcSEcCtD
Deferoxamine—Thrombocytopenia—Thiotepa—sarcoma	0.000821	0.00302	CcSEcCtD
Deferoxamine—Tachycardia—Thiotepa—sarcoma	0.000818	0.00301	CcSEcCtD
Deferoxamine—Leukopenia—Vincristine—sarcoma	0.000815	0.003	CcSEcCtD
Deferoxamine—Thrombocytopenia—Dactinomycin—sarcoma	0.000815	0.00299	CcSEcCtD
Deferoxamine—Skin disorder—Thiotepa—sarcoma	0.000814	0.00299	CcSEcCtD
Deferoxamine—Cramps of lower extremities—Doxorubicin—sarcoma	0.000804	0.00296	CcSEcCtD
Deferoxamine—Leukopenia—Mitoxantrone—sarcoma	0.000794	0.00292	CcSEcCtD
Deferoxamine—Eye disorder—Etoposide—sarcoma	0.000792	0.00291	CcSEcCtD
Deferoxamine—Convulsion—Vincristine—sarcoma	0.000789	0.0029	CcSEcCtD
Deferoxamine—Hepatic function abnormal—Epirubicin—sarcoma	0.000786	0.00289	CcSEcCtD
Deferoxamine—Myalgia—Vincristine—sarcoma	0.000775	0.00285	CcSEcCtD
Deferoxamine—Angiopathy—Etoposide—sarcoma	0.000769	0.00283	CcSEcCtD
Deferoxamine—Convulsion—Mitoxantrone—sarcoma	0.000769	0.00282	CcSEcCtD
Deferoxamine—Immune system disorder—Etoposide—sarcoma	0.000766	0.00281	CcSEcCtD
Deferoxamine—Mediastinal disorder—Etoposide—sarcoma	0.000764	0.00281	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Thiotepa—sarcoma	0.000764	0.00281	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Dactinomycin—sarcoma	0.000758	0.00279	CcSEcCtD
Deferoxamine—Arthralgia—Mitoxantrone—sarcoma	0.000755	0.00278	CcSEcCtD
Deferoxamine—Myalgia—Mitoxantrone—sarcoma	0.000755	0.00278	CcSEcCtD
Deferoxamine—Paraesthesia—Thiotepa—sarcoma	0.000753	0.00277	CcSEcCtD
Deferoxamine—Renal failure acute—Epirubicin—sarcoma	0.000744	0.00273	CcSEcCtD
Deferoxamine—Anaphylactic shock—Vincristine—sarcoma	0.000743	0.00273	CcSEcCtD
Deferoxamine—Oedema—Vincristine—sarcoma	0.000743	0.00273	CcSEcCtD
Deferoxamine—Infection—Vincristine—sarcoma	0.000739	0.00271	CcSEcCtD
Deferoxamine—Nervous system disorder—Vincristine—sarcoma	0.000729	0.00268	CcSEcCtD
Deferoxamine—Thrombocytopenia—Vincristine—sarcoma	0.000728	0.00267	CcSEcCtD
Deferoxamine—Hepatic function abnormal—Doxorubicin—sarcoma	0.000727	0.00267	CcSEcCtD
Deferoxamine—Anaphylactic shock—Mitoxantrone—sarcoma	0.000724	0.00266	CcSEcCtD
Deferoxamine—Oedema—Mitoxantrone—sarcoma	0.000724	0.00266	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Thiotepa—sarcoma	0.000724	0.00266	CcSEcCtD
Deferoxamine—Renal impairment—Epirubicin—sarcoma	0.000722	0.00265	CcSEcCtD
Deferoxamine—Infection—Mitoxantrone—sarcoma	0.000719	0.00264	CcSEcCtD
Deferoxamine—Pain—Thiotepa—sarcoma	0.000717	0.00263	CcSEcCtD
Deferoxamine—Shock—Mitoxantrone—sarcoma	0.000712	0.00262	CcSEcCtD
Deferoxamine—Pain—Dactinomycin—sarcoma	0.000712	0.00261	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Epirubicin—sarcoma	0.00071	0.00261	CcSEcCtD
Deferoxamine—Muscle spasms—Etoposide—sarcoma	0.000709	0.00261	CcSEcCtD
Deferoxamine—Thrombocytopenia—Mitoxantrone—sarcoma	0.000709	0.0026	CcSEcCtD
Deferoxamine—Tachycardia—Mitoxantrone—sarcoma	0.000707	0.0026	CcSEcCtD
Deferoxamine—Skin disorder—Mitoxantrone—sarcoma	0.000703	0.00258	CcSEcCtD
Deferoxamine—Hypotension—Vincristine—sarcoma	0.000695	0.00255	CcSEcCtD
Deferoxamine—Renal failure acute—Doxorubicin—sarcoma	0.000688	0.00253	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Thiotepa—sarcoma	0.000686	0.00252	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Dactinomycin—sarcoma	0.00068	0.0025	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Vincristine—sarcoma	0.000677	0.00249	CcSEcCtD
Deferoxamine—Hypotension—Mitoxantrone—sarcoma	0.000676	0.00249	CcSEcCtD
Deferoxamine—Renal impairment—Doxorubicin—sarcoma	0.000668	0.00245	CcSEcCtD
Deferoxamine—Paraesthesia—Vincristine—sarcoma	0.000668	0.00245	CcSEcCtD
Deferoxamine—Urticaria—Thiotepa—sarcoma	0.000666	0.00245	CcSEcCtD
Deferoxamine—Body temperature increased—Thiotepa—sarcoma	0.000663	0.00244	CcSEcCtD
Deferoxamine—Abdominal pain—Thiotepa—sarcoma	0.000663	0.00244	CcSEcCtD
Deferoxamine—Leukopenia—Etoposide—sarcoma	0.00066	0.00243	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Mitoxantrone—sarcoma	0.00066	0.00242	CcSEcCtD
Deferoxamine—Body temperature increased—Dactinomycin—sarcoma	0.000658	0.00242	CcSEcCtD
Deferoxamine—Abdominal pain—Dactinomycin—sarcoma	0.000658	0.00242	CcSEcCtD
Deferoxamine—Anaphylactoid reaction—Doxorubicin—sarcoma	0.000657	0.00241	CcSEcCtD
Deferoxamine—Paraesthesia—Mitoxantrone—sarcoma	0.00065	0.00239	CcSEcCtD
Deferoxamine—Dyspnoea—Mitoxantrone—sarcoma	0.000645	0.00237	CcSEcCtD
Deferoxamine—Blood creatinine increased—Epirubicin—sarcoma	0.000643	0.00236	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Vincristine—sarcoma	0.000642	0.00236	CcSEcCtD
Deferoxamine—Convulsion—Etoposide—sarcoma	0.000639	0.00235	CcSEcCtD
Deferoxamine—Pain—Vincristine—sarcoma	0.000636	0.00234	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.000624	0.00229	CcSEcCtD
Deferoxamine—Pain—Mitoxantrone—sarcoma	0.000619	0.00227	CcSEcCtD
Deferoxamine—Hypersensitivity—Thiotepa—sarcoma	0.000618	0.00227	CcSEcCtD
Deferoxamine—Hypersensitivity—Dactinomycin—sarcoma	0.000613	0.00225	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Vincristine—sarcoma	0.000608	0.00223	CcSEcCtD
Deferoxamine—Anaphylactic shock—Etoposide—sarcoma	0.000602	0.00221	CcSEcCtD
Deferoxamine—Infection—Etoposide—sarcoma	0.000598	0.0022	CcSEcCtD
Deferoxamine—Blood creatinine increased—Doxorubicin—sarcoma	0.000595	0.00219	CcSEcCtD
Deferoxamine—Asthma—Epirubicin—sarcoma	0.000594	0.00218	CcSEcCtD
Deferoxamine—Pruritus—Thiotepa—sarcoma	0.000593	0.00218	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Mitoxantrone—sarcoma	0.000592	0.00218	CcSEcCtD
Deferoxamine—Thrombocytopenia—Etoposide—sarcoma	0.00059	0.00217	CcSEcCtD
Deferoxamine—Tachycardia—Etoposide—sarcoma	0.000588	0.00216	CcSEcCtD
Deferoxamine—Eosinophilia—Epirubicin—sarcoma	0.000588	0.00216	CcSEcCtD
Deferoxamine—Body temperature increased—Vincristine—sarcoma	0.000588	0.00216	CcSEcCtD
Deferoxamine—Abdominal pain—Vincristine—sarcoma	0.000588	0.00216	CcSEcCtD
Deferoxamine—Skin disorder—Etoposide—sarcoma	0.000585	0.00215	CcSEcCtD
Deferoxamine—Urticaria—Mitoxantrone—sarcoma	0.000575	0.00211	CcSEcCtD
Deferoxamine—Diarrhoea—Thiotepa—sarcoma	0.000574	0.00211	CcSEcCtD
Deferoxamine—Abdominal pain—Mitoxantrone—sarcoma	0.000572	0.0021	CcSEcCtD
Deferoxamine—Body temperature increased—Mitoxantrone—sarcoma	0.000572	0.0021	CcSEcCtD
Deferoxamine—Diarrhoea—Dactinomycin—sarcoma	0.000569	0.00209	CcSEcCtD
Deferoxamine—Hypotension—Etoposide—sarcoma	0.000563	0.00207	CcSEcCtD
Deferoxamine—Dysuria—Epirubicin—sarcoma	0.000555	0.00204	CcSEcCtD
Deferoxamine—Dizziness—Thiotepa—sarcoma	0.000554	0.00204	CcSEcCtD
Deferoxamine—Asthma—Doxorubicin—sarcoma	0.000549	0.00202	CcSEcCtD
Deferoxamine—Hypersensitivity—Vincristine—sarcoma	0.000548	0.00201	CcSEcCtD
Deferoxamine—Eosinophilia—Doxorubicin—sarcoma	0.000544	0.002	CcSEcCtD
Deferoxamine—Paraesthesia—Etoposide—sarcoma	0.000541	0.00199	CcSEcCtD
Deferoxamine—Dyspnoea—Etoposide—sarcoma	0.000537	0.00197	CcSEcCtD
Deferoxamine—Hypersensitivity—Mitoxantrone—sarcoma	0.000533	0.00196	CcSEcCtD
Deferoxamine—Vomiting—Thiotepa—sarcoma	0.000533	0.00196	CcSEcCtD
Deferoxamine—Infestation NOS—Epirubicin—sarcoma	0.000529	0.00194	CcSEcCtD
Deferoxamine—Infestation—Epirubicin—sarcoma	0.000529	0.00194	CcSEcCtD
Deferoxamine—Vomiting—Dactinomycin—sarcoma	0.000529	0.00194	CcSEcCtD
Deferoxamine—Headache—Thiotepa—sarcoma	0.000525	0.00193	CcSEcCtD
Deferoxamine—Renal failure—Epirubicin—sarcoma	0.00052	0.00191	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Etoposide—sarcoma	0.00052	0.00191	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Epirubicin—sarcoma	0.000519	0.00191	CcSEcCtD
Deferoxamine—Pain—Etoposide—sarcoma	0.000515	0.00189	CcSEcCtD
Deferoxamine—Dysuria—Doxorubicin—sarcoma	0.000514	0.00189	CcSEcCtD
Deferoxamine—Diarrhoea—Vincristine—sarcoma	0.000509	0.00187	CcSEcCtD
Deferoxamine—Nausea—Thiotepa—sarcoma	0.000498	0.00183	CcSEcCtD
Deferoxamine—Diarrhoea—Mitoxantrone—sarcoma	0.000495	0.00182	CcSEcCtD
Deferoxamine—Nausea—Dactinomycin—sarcoma	0.000494	0.00182	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Etoposide—sarcoma	0.000492	0.00181	CcSEcCtD
Deferoxamine—Dizziness—Vincristine—sarcoma	0.000492	0.00181	CcSEcCtD
Deferoxamine—Infestation NOS—Doxorubicin—sarcoma	0.00049	0.0018	CcSEcCtD
Deferoxamine—Infestation—Doxorubicin—sarcoma	0.00049	0.0018	CcSEcCtD
Deferoxamine—Bradycardia—Epirubicin—sarcoma	0.000484	0.00178	CcSEcCtD
Deferoxamine—Renal failure—Doxorubicin—sarcoma	0.000481	0.00177	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Doxorubicin—sarcoma	0.00048	0.00176	CcSEcCtD
Deferoxamine—Urticaria—Etoposide—sarcoma	0.000478	0.00176	CcSEcCtD
Deferoxamine—Abdominal pain—Etoposide—sarcoma	0.000476	0.00175	CcSEcCtD
Deferoxamine—Body temperature increased—Etoposide—sarcoma	0.000476	0.00175	CcSEcCtD
Deferoxamine—Vomiting—Vincristine—sarcoma	0.000473	0.00174	CcSEcCtD
Deferoxamine—Urinary tract disorder—Epirubicin—sarcoma	0.000469	0.00172	CcSEcCtD
Deferoxamine—Connective tissue disorder—Epirubicin—sarcoma	0.000467	0.00172	CcSEcCtD
Deferoxamine—Urethral disorder—Epirubicin—sarcoma	0.000466	0.00171	CcSEcCtD
Deferoxamine—Headache—Vincristine—sarcoma	0.000466	0.00171	CcSEcCtD
Deferoxamine—Vomiting—Mitoxantrone—sarcoma	0.00046	0.00169	CcSEcCtD
Deferoxamine—Visual impairment—Epirubicin—sarcoma	0.000458	0.00168	CcSEcCtD
Deferoxamine—Headache—Mitoxantrone—sarcoma	0.000454	0.00167	CcSEcCtD
Deferoxamine—Bradycardia—Doxorubicin—sarcoma	0.000448	0.00164	CcSEcCtD
Deferoxamine—Eye disorder—Epirubicin—sarcoma	0.000444	0.00163	CcSEcCtD
Deferoxamine—Hypersensitivity—Etoposide—sarcoma	0.000444	0.00163	CcSEcCtD
Deferoxamine—Tinnitus—Epirubicin—sarcoma	0.000443	0.00163	CcSEcCtD
Deferoxamine—Nausea—Vincristine—sarcoma	0.000442	0.00162	CcSEcCtD
Deferoxamine—Urinary tract disorder—Doxorubicin—sarcoma	0.000434	0.0016	CcSEcCtD
Deferoxamine—Connective tissue disorder—Doxorubicin—sarcoma	0.000432	0.00159	CcSEcCtD
Deferoxamine—Angiopathy—Epirubicin—sarcoma	0.000431	0.00158	CcSEcCtD
Deferoxamine—Urethral disorder—Doxorubicin—sarcoma	0.000431	0.00158	CcSEcCtD
Deferoxamine—Nausea—Mitoxantrone—sarcoma	0.00043	0.00158	CcSEcCtD
Deferoxamine—Immune system disorder—Epirubicin—sarcoma	0.000429	0.00158	CcSEcCtD
Deferoxamine—Mediastinal disorder—Epirubicin—sarcoma	0.000428	0.00157	CcSEcCtD
Deferoxamine—Pruritus—Etoposide—sarcoma	0.000426	0.00157	CcSEcCtD
Deferoxamine—Arrhythmia—Epirubicin—sarcoma	0.000424	0.00156	CcSEcCtD
Deferoxamine—Visual impairment—Doxorubicin—sarcoma	0.000424	0.00156	CcSEcCtD
Deferoxamine—Erythema—Epirubicin—sarcoma	0.000414	0.00152	CcSEcCtD
Deferoxamine—Diarrhoea—Etoposide—sarcoma	0.000412	0.00151	CcSEcCtD
Deferoxamine—Eye disorder—Doxorubicin—sarcoma	0.000411	0.00151	CcSEcCtD
Deferoxamine—Tinnitus—Doxorubicin—sarcoma	0.00041	0.00151	CcSEcCtD
Deferoxamine—Angiopathy—Doxorubicin—sarcoma	0.000399	0.00147	CcSEcCtD
Deferoxamine—Dizziness—Etoposide—sarcoma	0.000398	0.00146	CcSEcCtD
Deferoxamine—Muscle spasms—Epirubicin—sarcoma	0.000398	0.00146	CcSEcCtD
Deferoxamine—Immune system disorder—Doxorubicin—sarcoma	0.000397	0.00146	CcSEcCtD
Deferoxamine—Mediastinal disorder—Doxorubicin—sarcoma	0.000396	0.00146	CcSEcCtD
Deferoxamine—Arrhythmia—Doxorubicin—sarcoma	0.000393	0.00144	CcSEcCtD
Deferoxamine—Vision blurred—Epirubicin—sarcoma	0.00039	0.00143	CcSEcCtD
Deferoxamine—Vomiting—Etoposide—sarcoma	0.000383	0.00141	CcSEcCtD
Deferoxamine—Erythema—Doxorubicin—sarcoma	0.000383	0.00141	CcSEcCtD
Deferoxamine—Headache—Etoposide—sarcoma	0.000377	0.00139	CcSEcCtD
Deferoxamine—Leukopenia—Epirubicin—sarcoma	0.00037	0.00136	CcSEcCtD
Deferoxamine—Muscle spasms—Doxorubicin—sarcoma	0.000368	0.00135	CcSEcCtD
Deferoxamine—Vision blurred—Doxorubicin—sarcoma	0.000361	0.00133	CcSEcCtD
Deferoxamine—Convulsion—Epirubicin—sarcoma	0.000358	0.00132	CcSEcCtD
Deferoxamine—Nausea—Etoposide—sarcoma	0.000358	0.00131	CcSEcCtD
Deferoxamine—Myalgia—Epirubicin—sarcoma	0.000352	0.00129	CcSEcCtD
Deferoxamine—Arthralgia—Epirubicin—sarcoma	0.000352	0.00129	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.00035	0.00129	CcSEcCtD
Deferoxamine—Leukopenia—Doxorubicin—sarcoma	0.000343	0.00126	CcSEcCtD
Deferoxamine—Anaphylactic shock—Epirubicin—sarcoma	0.000338	0.00124	CcSEcCtD
Deferoxamine—Oedema—Epirubicin—sarcoma	0.000338	0.00124	CcSEcCtD
Deferoxamine—Infection—Epirubicin—sarcoma	0.000335	0.00123	CcSEcCtD
Deferoxamine—Shock—Epirubicin—sarcoma	0.000332	0.00122	CcSEcCtD
Deferoxamine—Convulsion—Doxorubicin—sarcoma	0.000332	0.00122	CcSEcCtD
Deferoxamine—Nervous system disorder—Epirubicin—sarcoma	0.000331	0.00122	CcSEcCtD
Deferoxamine—Thrombocytopenia—Epirubicin—sarcoma	0.000331	0.00121	CcSEcCtD
Deferoxamine—Tachycardia—Epirubicin—sarcoma	0.000329	0.00121	CcSEcCtD
Deferoxamine—Skin disorder—Epirubicin—sarcoma	0.000328	0.0012	CcSEcCtD
Deferoxamine—Myalgia—Doxorubicin—sarcoma	0.000326	0.0012	CcSEcCtD
Deferoxamine—Arthralgia—Doxorubicin—sarcoma	0.000326	0.0012	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.000324	0.00119	CcSEcCtD
Deferoxamine—XDH—Metabolism—ENO2—sarcoma	0.000322	0.00373	CbGpPWpGaD
Deferoxamine—XDH—Metabolism—HBA1—sarcoma	0.00032	0.00371	CbGpPWpGaD
Deferoxamine—Hypotension—Epirubicin—sarcoma	0.000315	0.00116	CcSEcCtD
Deferoxamine—Anaphylactic shock—Doxorubicin—sarcoma	0.000312	0.00115	CcSEcCtD
Deferoxamine—Oedema—Doxorubicin—sarcoma	0.000312	0.00115	CcSEcCtD
Deferoxamine—Infection—Doxorubicin—sarcoma	0.00031	0.00114	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Epirubicin—sarcoma	0.000308	0.00113	CcSEcCtD
Deferoxamine—Shock—Doxorubicin—sarcoma	0.000307	0.00113	CcSEcCtD
Deferoxamine—Nervous system disorder—Doxorubicin—sarcoma	0.000306	0.00113	CcSEcCtD
Deferoxamine—Thrombocytopenia—Doxorubicin—sarcoma	0.000306	0.00112	CcSEcCtD
Deferoxamine—Tachycardia—Doxorubicin—sarcoma	0.000305	0.00112	CcSEcCtD
Deferoxamine—Skin disorder—Doxorubicin—sarcoma	0.000303	0.00111	CcSEcCtD
Deferoxamine—Paraesthesia—Epirubicin—sarcoma	0.000303	0.00111	CcSEcCtD
Deferoxamine—Dyspnoea—Epirubicin—sarcoma	0.000301	0.00111	CcSEcCtD
Deferoxamine—Hypotension—Doxorubicin—sarcoma	0.000292	0.00107	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Epirubicin—sarcoma	0.000291	0.00107	CcSEcCtD
Deferoxamine—Pain—Epirubicin—sarcoma	0.000289	0.00106	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Doxorubicin—sarcoma	0.000285	0.00105	CcSEcCtD
Deferoxamine—Paraesthesia—Doxorubicin—sarcoma	0.00028	0.00103	CcSEcCtD
Deferoxamine—Dyspnoea—Doxorubicin—sarcoma	0.000278	0.00102	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Epirubicin—sarcoma	0.000276	0.00101	CcSEcCtD
Deferoxamine—XDH—Metabolism—PLCG1—sarcoma	0.000273	0.00317	CbGpPWpGaD
Deferoxamine—Gastrointestinal disorder—Doxorubicin—sarcoma	0.00027	0.000991	CcSEcCtD
Deferoxamine—Urticaria—Epirubicin—sarcoma	0.000268	0.000985	CcSEcCtD
Deferoxamine—Pain—Doxorubicin—sarcoma	0.000267	0.000981	CcSEcCtD
Deferoxamine—Abdominal pain—Epirubicin—sarcoma	0.000267	0.000981	CcSEcCtD
Deferoxamine—Body temperature increased—Epirubicin—sarcoma	0.000267	0.000981	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Doxorubicin—sarcoma	0.000255	0.000939	CcSEcCtD
Deferoxamine—Hypersensitivity—Epirubicin—sarcoma	0.000249	0.000914	CcSEcCtD
Deferoxamine—Urticaria—Doxorubicin—sarcoma	0.000248	0.000912	CcSEcCtD
Deferoxamine—Abdominal pain—Doxorubicin—sarcoma	0.000247	0.000907	CcSEcCtD
Deferoxamine—Body temperature increased—Doxorubicin—sarcoma	0.000247	0.000907	CcSEcCtD
Deferoxamine—Pruritus—Epirubicin—sarcoma	0.000239	0.000878	CcSEcCtD
Deferoxamine—Diarrhoea—Epirubicin—sarcoma	0.000231	0.000849	CcSEcCtD
Deferoxamine—Hypersensitivity—Doxorubicin—sarcoma	0.00023	0.000846	CcSEcCtD
Deferoxamine—Dizziness—Epirubicin—sarcoma	0.000223	0.00082	CcSEcCtD
Deferoxamine—Pruritus—Doxorubicin—sarcoma	0.000221	0.000812	CcSEcCtD
Deferoxamine—Vomiting—Epirubicin—sarcoma	0.000215	0.000789	CcSEcCtD
Deferoxamine—Diarrhoea—Doxorubicin—sarcoma	0.000214	0.000785	CcSEcCtD
Deferoxamine—Headache—Epirubicin—sarcoma	0.000211	0.000777	CcSEcCtD
Deferoxamine—Dizziness—Doxorubicin—sarcoma	0.000207	0.000759	CcSEcCtD
Deferoxamine—Nausea—Epirubicin—sarcoma	0.000201	0.000737	CcSEcCtD
Deferoxamine—Vomiting—Doxorubicin—sarcoma	0.000199	0.00073	CcSEcCtD
Deferoxamine—Headache—Doxorubicin—sarcoma	0.000196	0.000719	CcSEcCtD
Deferoxamine—Nausea—Doxorubicin—sarcoma	0.000186	0.000682	CcSEcCtD
